A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

145

Participants

Timeline

Start Date

January 17, 2020

Primary Completion Date

May 14, 2024

Study Completion Date

December 31, 2025

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

PLB1001

PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.

Trial Locations (1)

Guangdong General Hospital, Guangzhou

All Listed Sponsors

lead

Beijing Pearl Biotechnology Limited Liability Company

INDUSTRY

NCT04258033 - A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG) | Biotech Hunter | Biotech Hunter